Cite
Luo R, Fan Y, Yang J, et al. A novel missense variant in ACAA1 contributes to early-onset Alzheimer's disease, impairs lysosomal function, and facilitates amyloid-β pathology and cognitive decline. Signal Transduct Target Ther. 2021;6(1):325doi: 10.1038/s41392-021-00748-4.
Luo, R., Fan, Y., Yang, J., Ye, M., Zhang, D. F., Guo, K., Li, X., Bi, R., Xu, M., Yang, L. X., Li, Y., Ran, X., Jiang, H. Y., Zhang, C., Tan, L., Sheng, N., & Yao, Y. G. (2021). A novel missense variant in ACAA1 contributes to early-onset Alzheimer's disease, impairs lysosomal function, and facilitates amyloid-β pathology and cognitive decline. Signal transduction and targeted therapy, 6(1), 325. https://doi.org/10.1038/s41392-021-00748-4
Luo, Rongcan, et al. "A novel missense variant in ACAA1 contributes to early-onset Alzheimer's disease, impairs lysosomal function, and facilitates amyloid-β pathology and cognitive decline." Signal transduction and targeted therapy vol. 6,1 (2021): 325. doi: https://doi.org/10.1038/s41392-021-00748-4
Luo R, Fan Y, Yang J, Ye M, Zhang DF, Guo K, Li X, Bi R, Xu M, Yang LX, Li Y, Ran X, Jiang HY, Zhang C, Tan L, Sheng N, Yao YG. A novel missense variant in ACAA1 contributes to early-onset Alzheimer's disease, impairs lysosomal function, and facilitates amyloid-β pathology and cognitive decline. Signal Transduct Target Ther. 2021 Aug 31;6(1):325. doi: 10.1038/s41392-021-00748-4. PMID: 34465723; PMCID: PMC8408221.
Copy
Download .nbib